BioMoti, Pharmidex and Queen Mary University of London secure £662,222 Biomedical Catalyst award

BioMoti, Pharmidex and Queen Mary University of London (QMUL) have been awarded a grant of £662,222 by the UK’s innovation agency, Innovate UK. The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard to treat tumours including advanced ovarian, triple negative breast and pancreatic cancers. […]

Read more
Professor Joanne Martin is President-Elect of The Royal College of Pathologists

Professor Joanne Martin, BioMoti co-founder and Director, has been elected by Fellows of The Royal College of Pathology to be their next president. Professor Martin was appointed President-Elect at the College’s Annual General Meeting. Professor Martin said: “I am very honoured that College Fellows have given me the opportunity to serve my College. I will […]

Read more
Physiomics Plc do not meet conditions to complete acquisition

Previously, BioMoti announced on 18th August 2016, the signature of a conditional Share Purchase Agreement to be acquired by Physiomics Plc (AIM: PYC). However, due to not meeting the main condition, Physiomics Plc raising a minimum of £1 million in a placing, the acquisition will not complete. Physiomics Plc did complete a placing of £555 […]

Read more
Signing of Share Purchase Agreement with Physiomics Plc

BioMoti is pleased to announce that it has signed a Share Purchase Agreement to be acquired by Physiomics Plc (AIM: PYC). This follows our announcement on 31st March 2016 of non-binding Heads of Terms agreement with Physiomics Plc. The acquisition remains conditional on Physiomics Plc completing a successful placing to raise a minimum of £1 […]

Read more
Non-Binding Heads of Terms with Physiomics Plc

BioMoti is pleased to announce that it has signed a non-binding Heads of Terms agreement to be acquired by Physiomics Plc (AIM: PYC). The Proposed Acquisition is currently conditional on a number of items, including due diligence and a successful equity fundraise. For more details, please click to read the Physiomics Plc regulatory update

Read more
BioMoti is featured in UK biotech documentary

Earlier this year, Dr Davidson Ateh, CEO, welcomed Philip Hemme and Joachim Eeckhout from LaBiotech Tour to Queen Mary University of London’s QMB Innovation Centre and Blizard Institute during their documentary tour of the UK’s biotech clusters. LaBiotech Tour is the first collection of documentary films about the world’s most vibrant biotech ecosystems. Find out […]

Read more
BioMoti is featured in the winter issue of the QMB Newsletter

Dr Davidson Ateh, CEO, discusses efforts to bring BioMoti to an international audience in this winter issue of the QMB Newsletter. The article reviews three trips to the US under UKTI support and a couple to China organised by the Open Innovation unit at the University of Bradford with sponsorship from Yorkshire Cancer Research and AstraZeneca. […]

Read more
Professor Linton and BioMoti awarded MRC Studentship

We are very pleased to announce the award of a Medical Research Council Industrial CASE Studentship to Professor Kenneth Linton of Queen Mary University of London in collaboration with BioMoti. This prestigious training grant will support a standout PhD student to study the basic cellular and molecular biology mechanisms underpinning ‘targeting cancer cells with CD95R-coated […]

Read more
BioMoti is shortlisted for OBN 2013 award

BioMoti is very pleased to announce that it is shortlisted in the Best Emerging Biotech category (Sponsored by James Cowper) alongside Atopix Therapeutics and Autifony Therapeutics for the OBN Awards 2013. The winners in each of ten categories will be announced at the OBN Annual Awards Dinner taking place on 1 October 2013 at the Ashmolean Museum of Art […]

Read more
BioMoti is featured in sp2 Inter-Active May/June 2013 issue

Dr Davidson Ateh, CEO, discusses BioMoti’s Oncojan™ intracellular drug delivery technology for cancer treatment with Tom Mulligan, Editor, in the May/June 2013 edition of sp2 Inter-Active. The article explores the origins of BioMoti, it’s technological capabilities, lead ovarian cancer candidate, business model, growth plans and the current context for early stage UK biotech companies. Click for article: BioMoti […]

Read more
Professor Joanne Martin is appointed National Clinical Director of Pathology

Professor Joanne Martin, BioMoti co-founder and Advisor, has been appointed by NHS Medical Director Professor Sir Bruce Keogh as the new National Clinical Director of Pathology for the NHS Commissioning Board. Jo, who is also Professor of Pathology at Queen Mary, University of London and Director of Academic Health Sciences at Barts Health NHS Trust, […]

Read more
BioMoti completes first private funding round

BioMoti, the cancer therapeutics co-development company, has completed an initial private finance round of £150,000 under the Seed Enterprise Investment Scheme (SEIS). The financing was led by the Oxford Technology OT(S)EIS Fund and an existing shareholder. The financing will be used to progress the Oncojan™ therapeutics delivery platform towards a regulatory compliant preclinical package that […]

Read more
BioMoti is awarded a £150,000 TSB Biomedical Catalyst grant

BioMoti is among the first SME recipients of the new £180 million Technology Strategy Board (TSB) Biomedical Catalyst funding programme. The scheme was set-up by the UK government earlier this year to provide responsive and effective support for the best life science opportunities arising in the UK. BioMoti will use this first TSB award to […]

Read more
BioMoti is runner-up at the coveted 2011 Genesis Awards

BioMoti is runner-up at this year’s prestigious Genesis Awards in the BioPharma innovation category along with Domainex and Thiologics. The category winner, announced at a special awards dinner following the conclusion of the Genesis 2011 conference on the first of December, was Immunocore. On the night, there was also a win for Scottish Health Innovations […]

Read more
BioMoti appoints Dr Keith Powell as new Chairman

BioMoti is pleased to announce the appointment of Dr Keith Powell as Chairman of the Board of Directors. Keith joins us with significant experience in the Biotech arena. He started his career at GSK and ICI/Zeneca in genetics and molecular biology where he led several large groups including Discovery and finally Intellectual Property. He then […]

Read more
BioMoti team awarded second BBSRC Follow-on-Fund grant

Professor Joanne Martin (principal applicant), Dr Davidson Ateh and Professor Iain McNeish (co-applicants) have started work on a second Biotechnology and Biological Sciences Research Council (BBSRC) Follow-on-Fund (FoF) grant at their academic laboratories at Queen Mary, University of London. The BBSRC FoF will support further preclinical validation studies on the exciting and innovative oncojan™ drug […]

Read more
Dr Davidson Ateh is runner-up at BBSRC Innovator of the Year 2011

Dr Davidson Ateh, CEO of BioMoti and Researcher at Queen Mary, University of London, was shortlisted for this year’s Biotechnology and Biological Sciences Research Council’s (BBSRC) Innovator of the Year award. The winners were announced at the Bioscience for Growth networking event that included keynote addresses by Jeremy Webb, Editor-in-Chief of New Scientist and Rt […]

Read more
Dr Davidson Ateh awarded “Commercial Innovation of the Year” prize

Dr Davidson Ateh, CEO of BioMoti, received the top prize of “Commercial Innovation of the Year” at the prestigious Healthcare Innovation Awards on the 4th of November 2010 hosted by Peter Morris OBE, Chief Executive of Barts and The London NHS Trust and organised by Barts and The London Joint R&D Office in collaboration with […]

Read more
Dr Davidson Ateh is profiled by BBSRC Business magazine

Dr Davidson Ateh, CEO of BioMoti and researcher at Queen Mary, University of London is profiled in the autumn edition of BBSRC Business magazine. In the interview Dr Ateh discusses the origins and aims of BioMoti and his personal journey towards technology entrepreneurship. Read the interview on the BBSRC website.

Read more
BioMoti strengthens business advisory board

BioMoti today announces the appointment of Dr Michael O’Neill to its business advisory board. Dr O’Neill is currently Managing Director at Eolas Biosciences and brings over 20 years experience in the pharmaceutical industry, working for Merck, Laboratorios Almirall and Eli Lilly. Dr Ateh, CEO of BioMoti said: “I am very happy to welcome Dr O’Neill […]

Read more
BioMoti forms business advisory board

BioMoti today announces the formation of a business advisory board to help guide it through the initial phases of development. Initial members include Mr Ian McFarlane-Toms who has previously held senior management posts in sales, marketing, operations and finance, both in the human and veterinary biotechnology sectors, Dr Marcel de Matas currently at the Institute […]

Read more
BioMoti is incorporated in England and Wales

Founders and Directors Dr Davidson Ateh and Prof Joanne Martin today announce that BioMoti Limited has been incorporated in England and Wales. BioMoti is set-up as the commercial vehicle to translate an innovative drug delivery technology from research project towards clinical development.

Read more
Dr Davidson Ateh is featured on PharmaTelevision

Dr Davidson Ateh, researcher at Queen Mary, University of London and Royal Society of Edinburgh/BBSRC Enterprise Fellow is featured on PharmaTelevision panel discussion: ‘Early Stage Spin Outs and the Road to Success’. In the programme presented by Dr Fintan Walton (CEO and Founder of PharmaVentures), Dr Ateh discusses the challenges new technology start-ups face in […]

Read more
Dr Davidson Ateh is awarded a Royal Society of Edinburgh/BBSRC Enterprise Fellowship

Dr Davidson Ateh, a researcher at Queen Mary, University of London was awarded a Royal Society of Edinburgh/BBSRC Enterprise Fellowship from Cabinet Secretary for Education and Lifelong Learning, Fiona Hyslop MSP and the President of the RSE, Sir Michael Atiyah, OM, PPRS, at a special awards ceremony on Friday 26 September in the Great Hall […]

Read more
Barts and The London team win first prize at Business Plan Lite Competition

Dr Davidson Ateh and Prof Joanne Martin of Barts and The London, Queen Mary’s School of Medicine and Dentistry along with Dr Laura Camurri of Queen Mary Innovation Ltd were today awarded first prize at the Business Plan Lite Competition organised by QM BioEnterprises for their plans to commercialise an innovative drug delivery technology. The […]

Read more